CELZ

Creative Medical Technology Holdings, Inc. · NASDAQ

Sector Health Technology
Industry Medical Specialties
Website creativemedicaltechnology.com
Employees(FY) 4
ISIN US22529Y4089

Performance

+3.49%

1W

-14.42%

1M

+5.22%

3M

+0.68%

6M

-3.47%

YTD

-32.58%

1Y

Profile

Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Advanced Technical Analysis

Technical Analysis of CELZ 2024-05-10

Overview:

In analyzing the technical indicators for CELZ over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and recommendations for potential in...

See more ...

Recent News & Updates

2024-05-12 22:54
CELZ Stock Earnings: Creative Medical Tech Beats EPS for Q1 2024(Investorplace)
2024-03-26 21:00
Creative Medical Technology Holdings Provides Corporate Update(Businesswire)
2024-03-06 22:04
Creative Medical (CELZ) Up on Orphan Drug Tag for CELZ-101(Zacks)
2024-03-06 20:15
Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access(Businesswire)
2024-03-05 18:00
Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy(Businesswire)
2023-12-19 20:35
Creative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back Pain(Accesswire)
2023-11-14 19:00
Creative Medical Technology Holdings Provides Corporate Update(Prnewswire)
2023-10-09 20:00
Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine using AlloStem ('CELZ-201-DDT') Novel Cell Therapy to Treat Chronic Lower Back Pain(Prnewswire)
2023-09-18 20:00
Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain(Yahoo Finance)
2023-08-23 22:45
What Is Allogeneic Cell Therapy, And Whats Driving This Markets 25%+ Annual Global Growth?(Yahoo Finance)
2023-07-12 21:00
Creative Medical Technology Reports Advancements In Regenerative Medicine And Improvements In Financial Position In Corporate Update(Yahoo Finance)
2023-06-27 20:00
Creative Medical Technology Holdings Regains Compliance With Nasdaq Listing Requirements(Yahoo Finance)
2023-06-11 20:01
Creative Medical Technology Announces $2 Million Share Repurchase Program(Yahoo Finance)
2023-06-11 20:00
Creative Medical Technology Holdings Provides Corporate Update(Yahoo Finance)
2023-06-09 00:30
Creative Medical Technology Holdings Announces Reverse Stock Split(Yahoo Finance)
2023-05-30 20:00
Creative Medical Technology Holdings Announces Successful Completion of the First Phase of its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz® Immunotherapy Platform(Yahoo Finance)
2023-05-21 20:30
Creative Medical Technology Holdings Announces Next Milestone Achievements in ImmCelz® Platform Development(Yahoo Finance)
2023-05-17 20:00
Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem Allogenic Cell Line(Yahoo Finance)
2023-05-13 20:13
Creative Medical Technology Holdings First Quarter 2023 Earnings: US$0.075 loss per share (vs US$0.18 loss in 1Q 2022)(Yahoo Finance)
2023-04-11 20:00
Creative Medical Technology Announces Positive Top-Line Results for Type 2 Diabetes Study(Yahoo Finance)
2023-04-03 20:00
Creative Medical Technology Holdings Announces Filing of 2022 Form 10-K and Provides Business Update(Yahoo Finance)
2023-03-22 20:00
Creative Medical Technology Files Orphan Drug Designation Application with the U.S. FDA Using the ImmCelz® Platform for the Treatment of Brittle Type 1 Diabetes(Yahoo Finance)
2023-03-20 20:00
Creative Medical Technology Holdings Announces Key Milestones Regarding ImmCelz® Platform Development(Yahoo Finance)
2023-03-06 19:00
Creative Medical Technology Holdings Engages Highly Respected International CRO for Phase 1 / 2 Clinical Trial to Treat Type 1 Diabetes Using CELZ-201(Yahoo Finance)
2023-02-13 19:00
Three Year Follow-Up Results Confirm Efficacy of StemSpine® Procedure for Treating Chronic Lower Back Pain, with No Serious Adverse Effects(Yahoo Finance)
2023-02-07 19:00
Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Novel Cell Therapy for the Treatment of Type 1 Diabetes(Yahoo Finance)
2022-11-02 19:30
Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem, a Novel Cell Therapy for the Treatment of Type 1 Diabetes(Yahoo Finance)
2022-10-19 20:00
Creative Medical Technology Holdings Develops AlloStem Clinical Cell Line(Yahoo Finance)
2022-09-25 20:00
Creative Medical Technology Announces Peer Reviewed Publication of Positive Results for StemSpine® Study(Yahoo Finance)
2022-07-27 19:30
Creative Medical Technology Announces Positive Top-Line Results for OvaStem® Pilot Study(Yahoo Finance)

Page 1 of 2

previousnext